Q32 Bio Inc. 8-K

What Happened
Q32 Bio Inc. (QTTB) announced on March 27, 2026 that it entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. to conduct an at-the-market (ATM) program. Under a prospectus supplement filed the same day and its effective Form S-3 shelf registration (File No. 333-286491), the company may offer and sell up to $14,200,000 aggregate principal amount of its common stock from time to time at its discretion.

Key Details

• Agreement date: March 27, 2026; prospectus supplement filed March 27, 2026; shelf registration (Form S-3) declared effective April 21, 2025.
• Maximum offering size: up to $14,200,000 of common stock to be sold at-the-market.
• Sales agent and fees: Cantor Fitzgerald & Co. acting as Sales Agent; Q32 will pay a cash commission equal to 3.0% of gross proceeds and will reimburse certain expenses.
• Mechanics and rights: sales may occur on Nasdaq or other trading markets; the company sets sale parameters and is not obligated to sell any shares; either party may suspend or terminate the program.

Why It Matters
This ATM program gives Q32 Bio flexibility to raise capital over time by selling shares at prevailing market prices rather than through a fixed-price offering. For investors, the key impacts are potential dilution if and when shares are sold and that net proceeds will be reduced by the 3.0% sales commission and reimbursable expenses. The agreement provides a ready source of capital for corporate needs while allowing the company to control timing and amount of issuance.